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Abstract Whilst randomised control trials are undoubtedly
the best way to demonstrate whether plasma exchange or
infusion alone is the best first-line treatment for patients
with atypical haemolytic uremic syndrome (aHUS), indi-
vidual case reports can provide valuable information. To
that effect, we have had the unique opportunity to follow
over a 10-year period three sisters with aHUS associated
with a factor H mutation (CFH). Two of the sisters are
monozygotic twins. A similar natural evolution and
response to treatment would be expected for the three
patients, as they all presented with the same at-risk
polymorphisms for CFH and CD46 and no identifiable
mutation in either CD46 or CFI. Our report of different
modalities of treatment of the initial episode and of three
transplantations and relapses in the transplant in two of
them, strongly suggest that intensive plasma exchange, both
acutely and prophylactically, can maintain the long-term
function of both native kidneys and allografts. In our
experience, the success of plasma therapy is dependent on
the use of plasma exchange as opposed to plasma infusion
alone, the prolongation of daily plasma exchange after
normalisation of haematological parameters followed by
prophylactic plasma exchange, the use of prophylactic
plasma exchange prior to transplantation and the use of
prophylactic plasma exchange at least once a week
posttransplant with immediate intensification of treatment
if there are any signs of recurrence.
Keywords Plasmaexchange.Plasmainfusion.Atypical
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Introduction
In ∼60% of patients with atypical haemolytic uremic
syndrome (aHUS), mutations have been detected in
complement components, including factor H (FH), mem-
brane cofactor protein, factor I, factor B and C3 [1–5].
Factor H abnormalities are the most frequent, being found
in ∼30% of patients. The prognosis in this group is poor,
with most patients developing end-stage renal failure
(ESRF) and a recurrence rate posttransplant of ∼80% [1,
6]. Although the use of plasma therapy is recommended,
there is little consensus either with regard to efficacy or the
optimal regimen to be used. To date, more than 100 FH
mutations have been described (http://www.fh-hus.org).
The penetrance of these mutations is ∼50%, suggesting
that other genetic and environmental factors act as
modifiers [4]. Retrospective analysis of the response to
plasma therapy in patients with FH mutations is supportive
of a beneficial effect [2, 3]. To that effect, we have had a
unique opportunity to follow over a 10-year period a family
of three sisters with aHUS associated with a FH mutation
(c.3572C>T, Ser1191Leu). The response to treatment has
been of particular interest, as two of the sisters are
monozygotic twins, and all three patients presented with
the same at-risk polymorphisms for CFH and CD46.
Therefore, they would be expected to present with a similar
natural evolution of the disease and treatment response.
Individual members of this family have been reported
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enables assessment of the effect of plasma therapy on the
natural history of the disease in both native kidneys and
allografts.
Case report
We summarise below our experience with plasma therapy
in three sisters, two of whom are monozygotic twins, with
atypical HUS associated with a FH mutation (c.3572C>T,
Ser1191Leu) (Table 1).
In all three sisters, serum FH concentration has always
been normal, and no evidence of systemic complement
activation (such as a low C3) has ever been detected.
Mutation screening of CFI and CD46 revealled no
abnormalities. Genotyping of the CD46 single nucleotide
polymorphism (SNP) *4074T>C (rs7144) showed that all
three sisters were heterozygous for the at-risk C allele.
Genotyping of CFH SNPs showed that all three sisters were
homozygous for the at-risk Tallele of -332C>T (rs3753394),
heterozygous for the at-risk G allele of c.2016A>G,
Q672Q (rs3753396) and heterozygous for the at-risk T
allele of c.2808G>T, E936D (rs1065489). Using multiplex
ligation-dependent probe amplification (MLPA), all three
sisters were found to have two copies of CFHR1 and
CFHR3.
The other family members (father, mother, an older
brother and an older sister) were asymptomatic. The disease
manifested first in the older sister when she was 3 years old
and resulted immediately in ESRF. Her first renal transplant
at the age of 5 years was lost to recurrent HUS within
weeks of surgery. Plasma therapy was not given at that
time.
Table 1 Clinical history of a family of three sisters presenting with factor H (FH) mutation-related haemolytic uremic syndrome (HUS)
Patients Older sister Twin 1 Twin 2
Native kidneys
Age (years) at presentation 3 4 4.5
PE (40 ml/kg/session) No 10 daily sessions initially 21 daily sessions initially
Pl Cr (μmol/l) response to
initial PE
166→ 137 132→ 61
PI (10 ml/kg) No 3 courses of 5 PI No
Prophylactic PE 1×2w No No Yes
Relapses Immediate ESRF 3 relapses of haemolysis and
thrombopenia
2 after 3 and 19 months,
respectively
Outcome Immediate ESRF Progressive degradation of renal
function. ESRF after 4 months
Pl Cr 66 μmol/l after
6 years, no urinary
abnormality
Tx 1 Cadaver Cadaver No
Prophylactic PE 1/w No plasma therapy Yes after initially prior Tx and daily
during 7 days post-Tx
Immunosuppressive
therapy
ATG, Pred, AZA, CsA Pred, MMF, CsA (low doses),
Basiliximab
Relapses 2 days after Tx no plasma therapy 2 relapses concomitant to CMV primo-
infection and reactivation; successful
treatment with daily PE and
ganciclovir
Outcome Transplantectomy P2 Cr 127 μmol/l 5 y after Tx
Tx2 Cadaver No No
Prophylactic PE 1/w During the first 2 month, after initially prior
Tx and daily during 7 days post-Tx
Prophylactic PE 1/2w Initiated 2 months post-Tx
Immunosuppressive
therapy
Pred, MMF, CsA(low dosis), Basiliximab
Relapse Occurred when PE frequency shift to 1/2w;
Outcome Immediate post-Tx function (Pl Cr 80 μmol/
l until day 60). Transplantectomy at day 75
related to late initiation of daily PE
PE plasma exchanges, PI plasma infusions, ESRF end-stage renal failure, Pl Cr plasma creatinine, Tx kidney transplantation, CMV
cytomegalovirus, Pred prednisone, MMF mycophenolate mofetil, CsA cyclosporin A, Aza azathioprine, ATG anti-thymocyte globulin
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the features of HUS. Plasma exchange (PE) was initiated,
and ten daily sessions of PE (40 ml/kg per session)
undertaken. Platelet count normalised, the evidence of
haemolysis resolved but plasma creatinine decreased only
slightly from 166 to 137 μmol/l. She received thereafter
three sessions of five plasma infusions (10 ml/kg) in
response to recurrent thrombocytopaenia and haemolysis
with good effect. However, plasma creatinine continued to
increase, and ESRF was reached 4 months after presentation.
Six months later, her twin sister (twin 2) presented with
the disease. Because of the dramatic evolution of the two
other sisters and the good response to plasma therapy in twin
1, an intensified plasma therapy protocol was implemented.
Daily PE was performed until normalisation of plasma
creatinine after 3 weeks (132 μmol/l to 61 μmol/l).
Thereafter, PE was undertaken once every 2 weeks. Three
and 19 months later, thrombocytopaenia and haemolysis in
association with a respiratory tract infection prompted a
temporary increase in the frequency of PE to daily.
Following the second relapse, weekly PE was undertaken
for 6 months, followed by a frequency of once every 2 weeks
indefinitely. There were no further relapses, and renal
function was normal six years after presentation.
This response to intensive PE prompted us to undertake
transplantation with prophylactic plasma therapy in her two
sisters. The older sister was transplanted for the second time
at the age of 12 years with a cadaver kidney. Immunosup-
pression comprised prednisone, cyclosporine (maximum
trough level 150 μg/ml), anti-interleukin-2-receptor (IL-2-R)
antibodies and mycophenolate mofetil. PE was undertaken
immediately prior to transplantation, daily for the first
postoperative week, and then progressively tapered to once
every 2 weeks by 2 months posttransplant. The graft
functioned well (plasma creatinine 80 μmol/l) until 2 months
posttransplant, when plasma creatinine increased to
200 μmol/l, without either evidence of thromboctyopaenia
or significant haemolysis. A clinical diagnosis of acute
rejection was made, and treatment commenced with pulse
methylprednisolone. A renal biopsy performed 5 days later
following a further deterioration in transplant function
showed HUS, and despite an increase in the frequency of
PE, the graft did not recover.
Twin 1 was the second to be transplanted, also with a
cadaver kidney. We used an identical immunosuppressive
regimen. PE was undertaken as in her older sister, but the
frequency of PE was never decreased to less than once a
week. There was immediate graft function, and plasma
creatinine fell to 80 μmol/l within days. Ten months
posttransplant, she presented with biopsy-proven recurrent
HUS associated with primary cytomegalovirus (CMV)
infection. The plasma creatinine was 167 μmol/l. After
4 weeks treatment with daily PE and ganciclovir, plasma
creatinine stabilised at 90 μmol/l. When ganciclovir was
stopped 6 months later, there was a further episode of
recurrent HUS, and plasma creatinine increased to
187 μmol/l. Again, intensification of PE and the use of
ganciclovir resulted in recovery of graft function. Contin-
uous CMV prophylaxis with acyclovir was instituted, and
no further episodes of either CMV reactivation or recurrent
HUS were seen. Five years after transplantation, plasma
creatinine was 127 μmol/l, and transplant biopsy showed
allograft nephropathy but no HUS activity.
PE was performed using plasma filtration technique with
a Gambro filter PF 1000 N and a Gambro device AK 200.
Reactions to plasma were rarely observed and were always
reversible using steroids and antihistaminic treatment.
Discussion
None of the affected members of this family showed
evidence of systemic complement activation. This is in
keeping with functional studies that show that mutations in
the C-terminal domains of FH lead to reduced binding to
surface-bound C3b and heparin, whereas the capacity to
bind fluid-phase C3b is maintained [11]. The FH mutation
(S1191L) found in the three affected sibs in this family has
been reported previously in another HUS patient [12].
Although the functional significance of this mutation has
not been examined, other missense mutations (W1183L,
V1197A, R1210C, R1215G) in the same complement-
control protein module (CCP 20) of FH have been shown to
result in impaired protection of host surfaces against
complement activation [11, 13]. It has been recently shown
that multiple additive factors, including both mutations and
susceptibility factors, in other complement genes are
probably responsible for the ×50% penetrance seen in
aHUS [4]. In these three patients, no mutations in either
CD46 or CFI were detected, and there was no evidence of
deletion of either CFHR1 or CFHR3,a sp r e v i o u s l y
described in association with aHUS [14]. However, all
three presented with the same at-risk polymorphisms of
CFH and CD46.
The efficacy of plasma therapy is difficult to assess in
recent large series, because treatment modalities are poorly
described [2, 3]. The general impression is that plasma
therapy is beneficial in patients known to have either a CFH
or CFI mutation, whereas it does not appear to influence the
outcome in patients with an MCP mutation [2, 3].
It is possible that the improvement seen in twin 2 after
her initial presentation was not related to PE, as spontaneous
recovery has been reported previously [2]. This is unlikely
because of the severity of the disease in her two sisters and
the similar profile of CFH and CD46 susceptibility factors
in the three patients. Our observation confirms previous
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with FH deficiency [2, 3, 15–18]. It confirms also that
plasma infusions do not always prevent deterioration of
renal function or relapses, even when given prophylactically
[18]. A possible cause of the failure of plasma infusion
treatment reported in the latter study as well in twin 1 in
this study may be that the volume of plasma allowed by
infusion alone (10 ml/kg) is four times less than the amount
used in PE. Another possible cause may be the type of
mutation and the resulting functional defect. In the report of
Nathanson and coworkers, a child with total FH deficiency
due to a homozygous CFH mutation was successfully treated
with plasma infusions [17]. In this patient, 13.5 ml/kg of
fresh frozen plasma infused every 2 weeks was associated
with a relapse-free period of several years. A similar
successful short-term outcome was seen in another patient
with complete FH deficiency by using plasma infusions
(20 ml/kg) both during relapses and prophylactically [16].
The duration of the daily PE treatment may also be
important, as the initial episode in twin 1 was treated daily
for 10 days compared with 3 weeks for twin 2. The degree of
renal failure at presentation does not seem to explain the
different responses to PE, as the difference between plasma
creatinine at treatment initiation in both twins was minimal
(166 vs. 132 μmol/l).
The risk of recurrence of aHUS in allografts is at least
20% [1] and is higher in patients known to have an FH
mutation [1]. The risk of early graft loss after recurrence in
some series of familial HUS is close to 100% despite
treatment [19]. For this reason, it has been suggested by
some that transplantation is contraindicated in familial HUS
[20]. A particularly high risk of relapse was observed in this
family, as the illness recurred in the three transplants
performed in two patients. However, PE profoundly
influenced the natural history of the disease both in native
kidney and transplants. The first transplant in the oldest
sister was performed without prophylactic PE and was
associated with immediate relapse and transplant loss. In
the same patient, the second transplant performed with
prophylactic PE had good function until 2 months post-
transplant. At that time, PE frequency was reduced to once
every 2 weeks, and at that time, there was a deterioration in
transplant function. This was initially felt to be secondary to
rejectionandintensificationofPE wasdelayed.Subsequently,
the graft was lost. The third transplant, performed in twin 1
under PE prophylaxis, resulted in satisfactory long-term
function (plasma creatinine 127 μmol/l after 5 years) despite
several relapses associated with CMV infection.
In conclusion, in this family with atypical HUS
associated with a FH mutation, we have shown that
intensive and prophylactic PE has enabled maintenance of
native and transplant renal function. The success of plasma
therapy was associated with the use of PE and not plasma
infusion, prolongation of daily PE after normalization of
haemolysis followed by prophylactic PE, the use of
prophylactic PE prior to transplantation and the use of a
minimum long-term PE frequency of once a week and
immediate intensification of PE frequency in case of
relapse.
As mutations of FH are heterogeneous, our strategy of
intensive and prophylactic PE may not be necessary in all
patients with FH mutations. Indeed, several authors have
reported success with plasma infusions [16, 17]. The
strategy of prophylactic PE is expensive, necessitates
creation of an arteriovenous fistula and implies life-long
regular treatment in hospital. It is likely that purified FH
will become available within the next few years, and this
may provide sufficient FH in a small volume to replace PE.
However, PE is not only a means to provide high volumes
of plasma but also removes mutant FH. Recently, success
has been obtained by combined kidney–liver transplanta-
tion with prophylactic PE immediately prior to transplan-
tation [21]. Treatment choice should take into account the
benefit versus risk as well as the local feasibility and
financial aspects.
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